Rowland Thomas Andrew 4
4 · ANI PHARMACEUTICALS INC · Filed Feb 13, 2026
Research Summary
AI-generated summary of this filing
ANI Pharmaceuticals (ANIP) SVP Rowland T. Andrew Withholds 1,762 Shares
What Happened
- Rowland T. Andrew, SVP & Head — Established Brands at ANI Pharmaceuticals, had 1,762 shares of ANI common stock disposed (withheld) to cover tax liabilities tied to the vesting of performance awards. The shares were valued at $76.25 each for a total of $134,353.
- The withholding is reported under transaction code F (tax withholding/cashless settlement) and relates to the vesting of 5,788 performance stock units previously granted.
Key Details
- Transaction date: 2026-02-11; filing date: 2026-02-13 (timely within typical reporting window).
- Price per share: $76.25; total value of shares withheld: $134,353.
- Filing footnote F1: Shares were withheld for tax purposes in connection with vesting of 5,788 performance stock units (grant previously reported).
- Filing footnote F2: Notes inclusion of 128 shares acquired under the company’s Employee Stock Purchase Plan in exempt transactions.
- Shares owned after the transaction: not specified in the provided summary of the filing.
Context
- This was a tax-withholding transaction (not an open-market sale). Companies often withhold or sell a portion of vested award shares to cover withholding obligations; such transactions are routine and do not necessarily indicate the insider’s view of the stock.
- For retail investors, outright purchases by insiders are generally more informative than withholding or routine disposals.
Insider Transaction Report
Form 4
Rowland Thomas Andrew
SVP, HEAD - ESTABLISHED BRANDS
Transactions
- Tax Payment
Common Stock
[F1][F2]2026-02-11$76.25/sh−1,762$134,353→ 39,160 total
Footnotes (2)
- [F1]Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 5,788 performance stock units, the grant of which was previously reported.
- [F2]Includes 128 shares of ANI Pharmaceuticals, Inc. Common Stock that were acquired under the ANI Pharmaceuticals, Inc. Employee Stock Purchase Plan in transactions that were exempt under Rule 16b-3(d) and Rule 16b-3(c).
Signature
/s/ Thomas Rowland, by attorney-in-fact Meredith W. Cook|2026-02-13